Why is Novo Nordisk excluding Hims & Hers in its lawsuits over Wegovy copies?
In Novo Nordisk's legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug Wegovy, one name remains conspicuously absent: Hims & Hers. The high-profile telehealth company continues to sell compounded versions of Wegovy at lower prices, testing the limits of federal restrictions on such copies and contributing to weaker sales growth for Novo.
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Hims & Hers Health (HIMS 1.49%) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again.
Hims & Hers Redefines Virtual Care With Integrated Tech Platforms
HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.
Hims & Hers: Still Growing After Breakup With Novo Nordisk
Hims & Hers is positioned as a leading telehealth platform targeting millennial and Gen Z consumers with affordable, accessible healthcare solutions. The company's strong revenue growth, expanding product offerings, and direct-to-consumer model support my positive outlook on the stock. HIMS's focus on recurring subscription revenue and high customer retention rates enhances long-term financial stability and growth potential.
Diagnosis: Hims & Hers' August Price Dip Is an Opportunity to Buy
Hims & Hers' NYSE: HIMS August price dip is an opportunity to buy, but investors shouldn't rush to get into this healthcare stock. Forces in play, including high short interest and tepid analyst involvement, are capping gains in 2025 and setting this market up for correction.
HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down
Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and subscriber growth.
What's Next For HIMS Stock?
Hims & Hers stock (NASDAQ: HIMS) fell approximately 13% in after-hours trading following Q2 results that demonstrated strong growth but did not meet revenue forecasts. The company disclosed revenue of $544.8 million, which reflects a strong 73% increase compared to the previous year, although it did not reach the $552 million consensus estimate.
Hims & Hers shares fall on mixed Q2 report, light revenue forecast
Hims & Hers (NYSE:HIMS) shares fell 12% before US markets opened on Tuesday as the company posted mixed results for the second quarter and issued cautious guidance. The company reported revenue of $544.8 million, up 73% year-over-year, but short of Wall Street estimates of $552 million.
Wall Street sets HIMS' stock price for the next 12 months
As telehealth company Hims & Hers Health (NYSE: HIMS) navigates a turbulent short-term period following a disappointing Q2 2025 earnings report, some on Wall Street are projecting extended losses for the stock.
Hims & Hers: Buy The Earnings Dip, Slowly (Rating Downgrade)
Despite a Q2 revenue miss and cash flow inflection into negative territory, Hims & Hers' long-term growth prospects remain intact due to ongoing platform broadening and international expansion. Management's ambitious vision, new C-suite hires, and $1B in fresh capital support aggressive growth plans, targeting $6.5B+ revenue and $1.3B+ EBITDA by 2030. While I have reduced our future growth assumptions and raised the modeling discount rate out of an abundance of caution, HIMS stock is still undervalued.
Hims & Hers Health, Inc. (HIMS) Q2 2025 Earnings Call Transcript
Hims & Hers Health, Inc. (NYSE:HIMS ) Q2 2025 Earnings Conference Call August 4, 2025 5:00 PM ET Company Participants Andrew Dudum - Co-Founder, Chairman & CEO Bill Newby - Head of Investor Relations Oluyemi Okupe - Chief Financial Officer Conference Call Participants Brian Gil Tanquilut - Jefferies LLC, Research Division Craig Matthew Hettenbach - Morgan Stanley, Research Division Daniel R. Grosslight - Citigroup Inc., Research Division David Michael Larsen - BTIG, LLC, Research Division Eric R.
